Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Speck

Urology Fredericksburg, TX Medical Doctor

NPI 1881733897 CMS profile 84996

1892 W US Highway 290, Fredericksburg, TX 78624

Open in the dashboard

General payments

$4,982

161 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Speck of Fredericksburg, TX is reported in the CMS Open Payments database as having received $4,982 across 161 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $729 32
2024 General $521 19
2023 General $565 23
2022 General $794 24
2021 General $579 18
2020 General $518 15
2019 General $1,278 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Speck
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Michael Speck were reported at $729. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Michael Speck Urology median Middle half National median
2019 $1,278 $480 $147–$1,201 $163
2020 $518 $246 $87–$645 $114
2021 $579 $358 $111–$1,000 $132
2022 $794 $476 $143–$1,263 $149
2023 $565 $560 $168–$1,461 $160
2024 $521 $563 $170–$1,464 $164
2025 $729 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Coloplast Corp $1,199 21 payments
  2. Astellas Pharma US Inc $491 13 payments
  3. Sanara MedTech Inc. $294 2 payments
  4. Sumitomo Pharma America, Inc. $294 14 payments
  5. Teleflex LLC $285 10 payments
  6. Urovant Sciences Inc $231 7 payments
  7. Innovation Technologies Inc $223 2 payments
  8. AbbVie, Inc. $172 8 payments
  9. Boston Scientific Corporation $165 9 payments
  10. Cook Medical LLC $139 5 payments
  11. Other $1,488 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,119 152 payments
  2. Travel and Lodging $470 2 payments
  3. Education $393 7 payments
Products named General payments · program years 2019–2025
  1. TITAN Penile Reconstruction $888 9 payments
  2. GEMTESA $508 20 payments
  3. CellerateRx $294 2 payments
  4. Irrisept $223 2 payments
  5. UROLIFT $182 9 payments
  6. Titan Men's Health $157 4 payments
  7. MYRBETRIQ $143 8 payments
  8. ERLEADA $136 9 payments
  9. PYLARIFY $133 5 payments
  10. UroLift System $128 3 payments
  11. Other $2,282 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

2,167

Median for Urology: 1,053

Drug cost

$377,170

Median for Urology: $101,464

Branded share of claims

34.1%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 179 $155,867
Thiola Ec Tiopronin Brand 11 $87,468
Gemtesa Vibegron Brand 86 $75,347
Mirabegron Er Mirabegron Brand 19 $14,808
Tamsulosin Hcl Generic 610 $11,094
Finasteride Generic 321 $5,191
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 69 $4,518
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 64 $3,998
Potassium Citrate Er Potassium Citrate Brand 42 $3,212
Methenamine Hippurate Generic 43 $2,804

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$227,841

Of which drugs: $19,311

Medicare patients

677

Average age 77

Services billed

3,082

179 women, 498 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Cancer 33%
Ischemic heart disease 29%
Diabetes 25%
Chronic kidney disease 25%
Atrial fibrillation 22%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 15 136 $19,128
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 20 40 $76
Injection, ceftriaxone sodium, per 250 mg J0696 Office 35 140 $51

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $64
$64 86 —
JELMYTO
  • UROGEN PHARMA, INC. $38
$38 — —
BOTOX
  • AbbVie, Inc. $25
$25 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $17
$17 — —
XIAFLEX
  • Endo USA, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

161 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record